EUVIMEDEUVIMED entdecken
Open Access

ZYS-1 is not an ADAR1 inhibitor

Cassandra N Smoak iD, Estelle N Gardner, Renee N Chua, Kyle A Cottrell iD

RNA · 2025-12 · 31 (12) · 1703-1711

DOI: 10.1261/rna.080721.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift RNA, online erschienen am 16.09.2025. Verfasst von Cassandra N Smoak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907, USA. Hauptthemen laut MEDLINE: Adenosine Deaminase, RNA-Binding Proteins, Adenosine Deaminase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMHD NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenosine deaminase acting on RNA 1 (ADAR1) edits double-stranded RNA (dsRNA) substrates by the deamination of adenosine to inosine in a process known as A-to-I editing. Modulation of ADAR1 expression and editing activity has previously been described to play a role in cancer development and progression, with upregulation of ADAR1 being observed in a range of cancers. Further, depletion of ADAR1 leads to increased sensing of endogenous dsRNAs by dsRNA sensors in cell lines that require ADAR1 for survival, which are termed ADAR1-dependent. The activation of these sensors induces downstream production of type I interferons as well as translational inhibition and apoptosis. Therefore, ADAR1 is a promising oncologic therapeutic target. Recently, the small molecule ZYS-1 has been developed and presented as a direct inhibitor of ADAR1. We performed a series of in vitro and cellular experiments to validate the efficacy and specificity of ZYS-1 as an ADAR1 inhibitor. Evaluating the effect of ZYS-1 on cell viability revealed it to be equally cytotoxic to both ADAR1-dependent and ADAR1-independent cell lines, as well as wild-type and ADAR1 knockout cells. Moreover, ZYS-1 treatment had little effect on activation of PKR or induction of IFN stimulated genes. Importantly, treatment with ZYS-1 did not reduce cellular A-to-I editing for several known ADAR1 editing sites and did not inhibit in vitro A-to-I editing by recombinant ADAR1. Together, these data indicate that ZYS-1 is not a selective inhibitor of ADAR1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine DeaminaseRNA-Binding ProteinsAdenosine Deaminase InhibitorsHumansRNA EditingCell SurvivalRNA, Double-StrandedCell Line, TumorApoptosis

Stichwörter der Autor:innen

ADAR1RNAcancer

Substanzen

Adenosine DeaminaseRNA-Binding ProteinsADAR protein, humanAdenosine Deaminase InhibitorsRNA, Double-Stranded

Autor:innen und Institutionen

  • Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907, USA.
  • Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907, USA kacottre@purdue.edu.
  • Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47907, USA.

ORCID-Profile: Cassandra N Smoak, Kyle A Cottrell

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Smoak, C. N., Gardner, E. N., Chua, R. N., & Cottrell, K. A. (2025). ZYS-1 is not an ADAR1 inhibitor. RNA, 31(12), 1703-1711. https://doi.org/10.1261/rna.080721.125

Vancouver

Smoak CN, Gardner EN, Chua RN, Cottrell KA. ZYS-1 is not an ADAR1 inhibitor. RNA. 2025;31(12):1703-1711. doi:10.1261/rna.080721.125

BibTeX
@article{Smoak2025,
  author = {Smoak, Cassandra N and Gardner, Estelle N and Chua, Renee N and Cottrell, Kyle A},
  title = {ZYS-1 is not an ADAR1 inhibitor},
  journal = {RNA},
  year = {2025},
  volume = {31},
  number = {12},
  pages = {1703--1711},
  doi = {10.1261/rna.080721.125}
}
Kostenlos starten →